Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China · Delayed Price · Currency is CNY | Market Cap | 20.07B |
| Revenue (ttm) | 3.26B |
| Net Income (ttm) | 303.28M |
| Shares Out | 420.73M |
| EPS (ttm) | 0.72 |
| PE Ratio | 66.21 |
| Forward PE | 26.08 |
| Dividend | 0.20 (0.42%) |
| Ex-Dividend Date | Jun 17, 2025 |
| Volume | 5,558,739 |
| Average Volume | 4,830,101 |
| Open | 48.00 |
| Previous Close | 48.12 |
| Day's Range | 47.15 - 48.29 |
| 52-Week Range | 46.51 - 79.80 |
| Beta | 0.65 |
| RSI | 31.27 |
| Earnings Date | Apr 16, 2026 |
About Betta Pharmaceuticals
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of NSCLC; and Bevacizumab, an antibody drug against human vascular endothelial growth factor that is used to treat NSCLC, colorectal ca... [Read more]
Financial Performance
In 2024, Betta Pharmaceuticals's revenue was 2.89 billion, an increase of 17.74% compared to the previous year's 2.46 billion. Earnings were 402.57 million, an increase of 15.67%.
Financial StatementsNews
Chinese healthcare, biotech firms flock to Hong Kong for IPOs
Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in th...